Drug Discovery & Development
News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.
During its R&D day, 23andMe outlined the genetics rationale for two cancer drugs it is developing and said it will apply genotyping across trials to identify best responders.
Eisbach Bio, MD Anderson Partner to Identify Synthetic Lethal Drug Targets
The Munich-based company will combine its discovery and assay platforms with MD Anderson's therapeutics discovery expertise to identify and research cancer drugs.
Lantern Pharma Collaborating With Danish Cancer Research Center on Drugs for NER-Deficient Tumors
They will use expanded mutational signature analyses to identify new biomarker-defined indications in multiple tumor types.
23andMe Gets $50M Payment as GSK Extends Companies' Drug Discovery Alliance
The companies are using 23andMe's extensive genotype-phenotype database and other resources to identify targets for personalized therapeutics, continuing an alliance begun in 2018.
Tempus, GSK Initiate Phase II Trial of Niraparib in PALB2-Mutated Tumors
Tempus will screen patients sequenced through its platform for PALB2 mutations to accelerate trial enrollment.